RxDoctor Payments Data

Barbara Bialowolska Romaniuk, MD

Internal Medicine · Surprise, AZNPI 1114946621

Payments from drug & device makers

$1,300in general payments, 2019–2025

Across 76 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$315
  • AbbVie$181
  • Pfizer$115
  • Sanofi-aventis U.S. LLC$78
  • Boston Scientific$74
  • Avanir Pharmaceuticals, Inc.$63
  • plus $474 from 19 others

What the payments were for

  • Food & beverage$1,28299%
  • Entertainment$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,300 in reported general payments places this provider in the 75th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$366,662
Medicare patients
619
Services billed
5,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$42,269
OzempicSemaglutide17$36,083
JanuviaSitagliptin Phosphate16$23,654
MounjaroTirzepatide16$22,835
FarxigaDapagliflozin Propanediol12$15,933
JanumetSitagliptin Phos/Metformin Hcl11$15,473
JardianceEmpagliflozin13$14,245
Atrovent HfaIpratropium Bromide11$4,986
LantusInsulin Glargine,hum.Rec.Anlog11$3,633
Levothyroxine Sodium331$3,293
SynthroidLevothyroxine Sodium44$3,038
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,724
Wixela InhubFluticasone Propion/Salmeterol16$2,603
Pantoprazole Sodium131$2,180
Omeprazole107$2,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$115$42,26931 claims
MerckJanuvia, Janumet$13$39,12627 claims
Novo NordiskOzempic$47$36,08317 claims
Lilly USA, LLCMounjaro$40$22,83516 claims
AstraZenecaFarxiga$315$15,93312 claims
Sanofi-aventis U.S. LLCLantus$78$3,63311 claims
AbbVieSynthroid$181$3,03844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →